Abortion Early Clinical Trial
Official title:
The California Home Abortion by Telehealth (CHAT) Study
This study aims to assess efficacy and safety outcomes of a telehealth model of abortion care. The study will compare efficacy of this model to usual in-clinic care based on published rates. It will also investigate participant acceptability and feasibility of this model of care.
There are 2 components to the study: 1. A clinical records review on all patients 2. A survey study on a subset of patients who agree to participate. Clinical Records Review: We will examine medical chart data on all patients from partnered telehealth providers to analyze efficacy and safety outcomes for medication abortion. These medical chart data will include medical/pregnancy history and abortion outcome and de-identified apart from date of birth, zip code, and dates of service. Survey Study: Following completion of the telehealth provider's standard medical screening, all patients eligible to receive care through the telehealth provider will be directed to a page providing detailed information about the CHAT Evaluation Study and given the option to participate. Participation in the study involves completing our online questionnaires only. Being in the research study will not affect their care or treatment plan. Declining to participate in our research study will not affect their care. If interested, the patient will provide electronic consent and complete a baseline survey to report socio-demographic characteristics, pregnancy history, and reasons for interest in telehealth medication abortion services. An online follow-up survey will be administered 3-7 days after receiving mifepristone and then once again 4 weeks after taking mifepristone; assessments will include self-report of medication administration, adverse events, and satisfaction. Among those who complete the study surveys, we will investigate the feasibility, time to abortion, efficacy, safety, and acceptability of telehealth provision of mifepristone, measured using a 4-week follow-up though open-ended and closed-ended survey questions. Individuals who opted not to take the medications will be asked a separate set of follow-up questions to collect data related to diversion, to better understand potential risks. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03989869 -
Very Early Medical Abortion
|
N/A | |
Active, not recruiting |
NCT03736681 -
Effect of Paracervical Block Volume on Pain Control for Dilation and Curettage
|
Phase 1 | |
Completed |
NCT03636451 -
Effect of Paracervical Block Volume on Pain Control for Dilation and Curettage.o
|
Phase 3 | |
Recruiting |
NCT05182008 -
A Patient Decision Aid for Method of Early Abortion: A Randomized Control Trial
|
N/A | |
Completed |
NCT03417362 -
Delivery of Audiovisual Information on Early Medical Abortion
|
N/A | |
Completed |
NCT04824118 -
Clotting Parameters After Medical Abortion
|
||
Recruiting |
NCT04458558 -
Improving Access to Abortion in the Republic of Georgia
|
Phase 4 | |
Active, not recruiting |
NCT05278780 -
Medication Abortion With Autonomous Self-Assessment Project
|
N/A | |
Completed |
NCT03320057 -
Medication Abortion Via Pharmacy Dispensing
|
Phase 4 | |
Not yet recruiting |
NCT05986357 -
The Relation of High Sensitivity C Reactive Protein and Total Leucocytic Count Levels in Threatened Abortion
|
||
Completed |
NCT03047551 -
Transabdominal and Transvaginal Sonography in Medical Abortion
|
N/A | |
Completed |
NCT03913104 -
Mail Order Mifepristone Study
|
Phase 4 | |
Terminated |
NCT04139382 -
Using Telemedicine to Improve Early Medical Abortion at Home
|
N/A | |
Recruiting |
NCT05147857 -
Mid Trimester Abortion Effectiveness by Dilapan s
|
N/A | |
Recruiting |
NCT05781061 -
MA-ASAP at Independent Abortion Clinics: A Demonstration Project
|
N/A | |
Completed |
NCT02522078 -
Dry vs Wet Misoprostol for Cervical Dilation in First Trimester Abortion
|
Phase 4 | |
Completed |
NCT05635955 -
Remimazolam Versus Propofol for Painless Abortion
|
Phase 2 | |
Active, not recruiting |
NCT05342974 -
Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy
|
Early Phase 1 | |
Completed |
NCT03900728 -
Auriculotherapy During Medication Abortion
|
N/A |